JP2025508963A5 - - Google Patents

Info

Publication number
JP2025508963A5
JP2025508963A5 JP2024552169A JP2024552169A JP2025508963A5 JP 2025508963 A5 JP2025508963 A5 JP 2025508963A5 JP 2024552169 A JP2024552169 A JP 2024552169A JP 2024552169 A JP2024552169 A JP 2024552169A JP 2025508963 A5 JP2025508963 A5 JP 2025508963A5
Authority
JP
Japan
Application number
JP2024552169A
Other languages
Japanese (ja)
Other versions
JPWO2023168326A5 (https=
JP2025508963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063559 external-priority patent/WO2023168326A2/en
Publication of JP2025508963A publication Critical patent/JP2025508963A/ja
Publication of JPWO2023168326A5 publication Critical patent/JPWO2023168326A5/ja
Publication of JP2025508963A5 publication Critical patent/JP2025508963A5/ja
Pending legal-status Critical Current

Links

JP2024552169A 2022-03-03 2023-03-02 ヒト化及び親和性成熟抗ceacam1抗体及びその使用方法 Pending JP2025508963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316140P 2022-03-03 2022-03-03
US63/316,140 2022-03-03
PCT/US2023/063559 WO2023168326A2 (en) 2022-03-03 2023-03-02 Humanized and affinity-matured anti-ceacam1 antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2025508963A JP2025508963A (ja) 2025-04-10
JPWO2023168326A5 JPWO2023168326A5 (https=) 2026-03-09
JP2025508963A5 true JP2025508963A5 (https=) 2026-03-09

Family

ID=87884376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552169A Pending JP2025508963A (ja) 2022-03-03 2023-03-02 ヒト化及び親和性成熟抗ceacam1抗体及びその使用方法

Country Status (7)

Country Link
US (1) US20250388666A1 (https=)
EP (1) EP4486380A2 (https=)
JP (1) JP2025508963A (https=)
CN (1) CN119032103A (https=)
AU (1) AU2023227877A1 (https=)
CA (1) CA3245215A1 (https=)
WO (1) WO2023168326A2 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2785743B1 (en) * 2011-12-01 2019-08-14 The Brigham and Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
JP2025508963A5 (https=)
BR102023014872A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13150U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13176U (https=)
BY13175U (https=)